Vadim J Gurvich
Overview
Explore the profile of Vadim J Gurvich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Boyce H, Smith D, Byrn S, Saluja B, Qu W, Gurvich V, et al.
AAPS PharmSciTech
. 2018 Mar;
19(4):1744-1757.
PMID: 29582347
In vitro evaluation of abuse deterrent formulations (ADFs) is a challenge since real abuse situations are variable and ADF technology is evolving. Specifically, an assessment of an ADF to deter...
12.
Patil S, Lis L, Schumacher R, Norris B, Morgan M, Cuellar R, et al.
J Med Chem
. 2015 Nov;
58(23):9334-44.
PMID: 26596892
A disodium phosphonooxymethyl prodrug of the antitumor agent triptolide was prepared from the natural product in three steps (39% yield) and displayed excellent aqueous solubility at pH 7.4 (61 mg/mL)...
13.
Kirtane A, Wong H, Guru B, Lis L, Georg G, Gurvich V, et al.
Mol Pharm
. 2015 Jun;
12(8):2912-23.
PMID: 26065924
Several promising anticancer drug candidates have been sidelined owing to their poor physicochemical properties or unfavorable pharmacokinetics, resulting in high overall cost of drug discovery and development. Use of alternative...
14.
Dosa P, Georg G, Gurvich V, Hawkinson J, Walters M, Wong H
Comb Chem High Throughput Screen
. 2014 Jan;
17(3):231-40.
PMID: 24409956
The high-throughput screening core at the University of Minnesota is part of the Institute for Therapeutics Discovery and Development (ITDD), a comprehensive drug discovery and development center. The Institute provides...
15.
Gurvich V, Byrn S
Drug Discov Today
. 2013 Jun;
18(19-20):916-21.
PMID: 23732177
The strategic goal of academic translational research is to accelerate translational science through the improvement and development of resources for moving discoveries across translational barriers through 'first in humans' studies....
16.
Stenland C, Lis L, Schendel F, Hahn N, Smart M, Miller A, et al.
Org Process Res Dev
. 2013 Feb;
17(2):265-272.
PMID: 23440664
A scalable and reliable manufacturing process for Nikkomycin Z HCl on a 170 g scale has been developed and optimized. The process is characterized by a 2.3 g/L fermentation yield,...
17.
Synthesis and Biological Evaluation of a Biotinylated Paclitaxel With an Extra-Long Chain Spacer Arm
Lis L, Smart M, Luchniak A, Gupta Jr M, Gurvich V
ACS Med Chem Lett
. 2012 Dec;
3(9):745-748.
PMID: 23259031
A biotinylated paclitaxel derivative with an extra-long-chain (LC-LC-Biotin) spacer arm was synthesized using an improved synthetic reaction sequence. The biotinylated paclitaxel analogue retained excellent microtubule stabilizing activity in vitro. Furthermore,...
18.
Benyumov A, Gurvich V, Lis L, Williams B, Kirstein M
ChemMedChem
. 2011 Feb;
6(3):457-64.
PMID: 21280228
Recent evidence has shown that the gemcitabine metabolite, dFdU, is pharmacologically active. Though less potent, dFdU has a longer half-life and could potentiate or antagonize the activity of gemcitabine. Hence,...